Close

Sign in
Sign up

Menu

Intel
Data search
Signals
Startup Concierge
Get intel

Home
News
Engimmune Therapeutics secured CHF15.5M from Novo and Pureos.

Engimmune Therapeutics secured CHF15.5M from Novo and Pureos.

Biotech Health services Manufacturing

Switzerland

Denmark

Investments

01 May 2022

Share:

Engimmune Therapeutics (company)

Switzerland

Biotech Health services Manufacturing

Total investments received (USD): 15.8m

Round value (USD): 15.8m

Round investors: Novo A/S Pureos Bioventures

Company: Engimmune Therapeutics

Industry: Biotech Health services Manufacturing

Related deals

Hedera to raise €14m in seed capital funding.

Biotech Health services

Switzerland

United Kingdom

Finland

Germany

United States

United Arab Emirates

Brazil

Investments 01 September 2022

Mootral raised more funding

Agriculture Biotech Energy Manufacturing Social Responsibility

Switzerland

United States

Investments 16 April 2022

Sidebar

Verticals

Financial Services
Food Industry
Education
E-commerce
Health services
Marketplace

Benelux

Belgium
Netherlands

DACH

Austria
Germany
Switzerland

Nordics and Baltics

Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden

Western Europe

France
Ireland
Italy
Portugal
Spain
United Kingdom

About
Contact
Terms of service
Privacy policy

© All rights reserved Nordic 9 2016-2026. Made with in Stockholm

Top